

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cardalis 2.5 mg/20 mg chewable tablets for dogs

Cardalis 5 mg/40 mg chewable tablets for dogs

Cardalis 10 mg/80 mg chewable tablets for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each chewable tablet contains:

Active substance:

	Benazepril hydrochloride (HCl) (benazeprilum HCl)	Spironolactone (spironolactonum)
Cardalis 2.5 mg/20 mg chewable tablets	2.5 mg	20 mg
Cardalis 5 mg/40 mg chewable tablets	5 mg	40 mg
Cardalis 10 mg/80 mg chewable tablets	10 mg	80 mg

Excipient:

Qualitative composition of excipients and other constituents
Lactose monohydrate
Cellulose, microcrystalline
Povidone K30
Artificial beef flavour
Compressible sugar
Crospovidone
Magnesium stearate

Brown palatable oblong shaped chewable tablets with a score line.

The chewable tablets can be divided into equal halves.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

For the treatment of congestive heart failure caused by chronic degenerative valvular disease in dogs (with diuretic support as appropriate).

3.3 Contraindications

Do not use during pregnancy and lactation (see section 3.7).

Do not use in dogs intended or used for breeding.

Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia.

Do not administer in conjunction with Non Steroidal Anti-Inflammatory Drugs (NSAIDs) to dogs with renal insufficiency.

Do not use in cases of hypersensitivity to Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) or to any of the excipients.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Kidney function and serum potassium levels should be evaluated before initiating the treatment with benazepril and spironolactone, especially in dogs which may suffer hypoadrenocorticism, hyperkalaemia or hyponatraemia. Unlike in humans, an increased incidence of hyperkalaemia was not observed in clinical trials performed in dogs with this combination. However, regular monitoring of renal function and serum potassium levels is recommended in dogs with renal impairment, as they may have an increased risk of hyperkalaemia during treatment with this veterinary medicinal product.

Due to the antiandrogenic effect of spironolactone, it is not recommended to administer the veterinary medicinal product to growing dogs.

Reversible prostatic atrophy in entire male dogs treated with spironolactone was noted in a Target Animal Safety study at the recommended dose.

The veterinary medicinal product should be used with caution in dogs with hepatic dysfunction because it may alter the extensive biotransformation of spironolactone in liver.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to spironolactone or benazepril should avoid contact with the veterinary medicinal product.

Pregnant women should take special care to avoid accidental oral exposure because ACE inhibitors have been found to affect the unborn child during pregnancy in humans.

Accidental ingestion, particularly by children, may lead to adverse events such as drowsiness, nausea and vomiting and diarrhoea, and skin rashes.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Vomiting, diarrhoea Pruritus Lethargy, fatigue, anorexia Ataxia, incoordination Elevated creatinine ¹
---	--

¹ May occur at the start of therapy in dogs with chronic kidney disease, due to benazepril action. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents and is therefore not necessarily a reason to stop therapy in the absence of other signs.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Do not use during pregnancy and lactation. Embryotoxic effects (foetal urinary tract malformation) were seen in trials of benazepril with laboratory animals (rats) at maternally non-toxic doses.

3.8 Interaction with other medicinal products and other forms of interaction

Furosemide has been used together with this combination of benazepril hydrochloride and spironolactone in dogs with heart failure without any clinical evidence of adverse interactions.

The concomitant administration of this veterinary medicinal product with other anti-hypertensive agents (e.g. calcium channel blockers, β -blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.

The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments (such as β -blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia (see section 3.5).

The concomitant use of NSAIDs with this veterinary medicinal product may reduce its anti-hypertensive effect, its natriuretic effect and increase the level of serum potassium. Therefore, dogs treated concomitantly with an NSAID should be closely monitored and correctly hydrated.

The administration of deoxycorticosterone with the veterinary medicinal product may lead to a moderate reduction of the natriuretic effects (reduction of urinary sodium excretion) of spironolactone.

Spironolactone decreases digoxin elimination and hence raises digoxin plasma concentration. As the therapeutic index for digoxin is very narrow, it is advisable to monitor closely dogs receiving both digoxin and a combination of benazepril hydrochloride and spironolactone.

Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could affect the metabolism of other substances utilizing these metabolic pathways. Therefore, the veterinary medicinal product should be used with caution with other veterinary medicinal products which induce, inhibit, or which are metabolised by these enzymes.

3.9 Administration routes and dosage

Oral use.

This fixed combination veterinary medicinal product should only be used in dogs which require both active substances to be administered concomitantly at this fixed dose.

The chewable tablets should be administered to the dog once a day at a dose of 0.25 mg/kg bodyweight (bw) benazepril hydrochloride (HCl) and 2 mg/kg bodyweight spironolactone, according to the following dosage table.

The chewable tablets should be administered with food, either mixed with a small amount of food offered to the dog just prior to the main meal, or with the meal itself. The chewable tablets contain beef flavouring to improve palatability, and in a field study conducted in dogs with chronic degenerative valvular disease the chewable tablets were voluntarily and fully consumed 92% of the time when offered either with or without food.

Bodyweight (kg) of dog	Strength and number of chewable tablets to be administered		
	Cardalis 2.5 mg/20 mg chewable tablets	Cardalis 5 mg/40 mg chewable tablets	Cardalis 10 mg/80 mg chewable tablets
2.5 - 5	½		
5 - 10	1		
10 - 20		1	
20 - 40			1
40 - 60			1 + ½
60 - 80			2

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

After administration of up to 10 times the recommended dose (2.5 mg/kg bw benazepril hydrochloride, 20 mg/kg bw spironolactone) to healthy dogs, dose dependant adverse events were noted (see section 3.6).

Daily overdoses to healthy dogs, that is, 6 times (1.5 mg/kg bw benazepril hydrochloride and 12 mg/kg bw spironolactone) and 10 times (2.5 mg/kg bw benazepril hydrochloride and 20 mg/kg bw spironolactone) the recommended dose, led to a slight dose related decrease in red cell mass. However, this very slight decrease was transient, the red cell mass remained within the normal range, and the finding was not considered to be of clinical importance. A dose related but moderate compensatory physiological hypertrophy of the *zona glomerulosa* of the adrenal glands was also observed at doses of 3 times and greater of the recommended dose. This hypertrophy does not seem to be linked to any pathology and was observed to be reversible upon discontinuation of the treatment.

In case of the accidental ingestion by a dog of many chewable tablets of the veterinary medicinal product, there is no specific antidote or treatment. It is therefore recommended to induce vomiting, and then carry out gastric lavage (depending on the risk assessment) and monitor electrolytes. Symptomatic treatment, e.g., fluid therapy, should also be provided.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code : QC09BA07.

4.2 Pharmacodynamics

Spironolactone and its active metabolites (including 7- α -thiomethyl-spironolactone and canrenone) act as specific antagonists of aldosterone by binding competitively to mineralocorticoid receptors located

in the kidneys, heart and blood vessels. In the kidney, spironolactone inhibits the aldosterone-induced sodium retention leading to increase in sodium, and subsequently water excretion, and potassium retention. The resulting reduction in extracellular volume decreases the cardiac preload and left atrial pressure. The result is an improvement in heart function. In the cardiovascular system, spironolactone prevents the detrimental effects of aldosterone. Aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction, although the precise mechanism of action is not yet clearly defined. In experimental models in dogs, it was shown that long term therapy with an aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure.

Benazepril hydrochloride is a prodrug hydrolysed *in vivo* into its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of angiotensin converting enzyme (ACE), thus preventing the conversion of inactive angiotensin I to active angiotensin II. Therefore, it blocks effects mediated by angiotensin II, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney.

The veterinary medicinal product causes a long-lasting inhibition of plasma ACE activity in dogs, with more than 95% inhibition at peak effect and significant activity (>80%) persisting 24 hours after dosing.

The association of spironolactone and benazepril is beneficial as both act on the renin-angiotensin-aldosterone system (RAAS) but at different levels along the cascade.

Benazepril, by preventing the formation of Angiotensin-II, inhibits the detrimental effects of vasoconstriction and stimulation of aldosterone release. However, aldosterone release is not fully controlled by ACE Inhibitors because Angiotensin-II is also produced by non-ACE pathways such as chymase (phenomenon known as “aldosterone breakthrough”). Secretion of aldosterone can also be stimulated by factors other than Angiotensin-II, notably K⁺ increase or ACTH. Therefore, to achieve a more complete inhibition of the deleterious effects of RAAS overactivity which occurs with heart failure, it is recommended to use aldosterone antagonists, such as spironolactone, concomitantly with ACE inhibitors to block specifically the activity of aldosterone (regardless of the source), through competitive antagonism on mineralocorticoid receptors. Clinical studies investigating the survival time demonstrated that the fixed combination increased the life expectancy in dogs with congestive heart failure with a 89% reduction in the relative risk of cardiac mortality assessed in dogs treated with spironolactone in combination with benazepril (as the hydrochloride) compared to dogs treated with benazepril (as hydrochloride) alone (mortality was classified as death or euthanasia due to heart failure). It also allowed a quicker improvement of cough and activity and a slower degradation of cough, heart sounds and appetite.

A slight increase in aldosterone blood levels may be observed in animals on treatment. This is thought to be due to activation of feedback mechanisms without adverse clinical consequence. There may be a dose related hypertrophy of the adrenal *zona glomerulosa* at high dose rates. In a field study conducted in dogs with chronic degenerative valvular disease 85.9% of dogs showed good compliance with treatment ($\geq 90\%$ of prescribed chewable tablets successfully administered) over a three-month period.

4.3 Pharmacokinetics

The pharmacokinetics of spironolactone are based on its metabolites, as the parent compound is unstable at assay.

Absorption

After oral administration of spironolactone to dogs, it was demonstrated that the three metabolites achieved levels of 32 to 49% of the administered dose. Food increases the bioavailability to 80 to 90%. Following oral administration of 2 to 4 mg/kg, absorption increases linearly over the range.

After multiple oral doses of 2 mg spironolactone per kg (with 0.25 mg benazepril hydrochloride per kg) for 7 consecutive days, no accumulation is observed. At steady state, mean C_{max} of 324 mcg/l and 66 mcg/l are achieved for the primary metabolites, 7- α -thiomethyl-spironolactone and canrenone, 2 and 4 hours post-dosing, respectively. Steady-state conditions are reached by day 2.

After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly and decline quickly as the active substance is partially metabolized by liver enzymes to benazeprilat. Unchanged benazepril and hydrophilic metabolites account for the remainder. The systemic bioavailability of benazepril is incomplete due to incomplete absorption and first pass metabolism. There is no significant difference in the pharmacokinetics of benazeprilat when benazepril (as hydrochloride) is administered to fed or fasted dogs.

After multiple oral doses of 0.25 mg benazepril hydrochloride per kg (with 2 mg spironolactone per kg) for 7 consecutive days, a peak benazeprilat concentration (C_{max} of 52.4 ng/ml) is achieved with a T_{max} of 1.4 h.

Distribution

The mean volumes of distribution of 7- α -thiomethyl-spironolactone and canrenone are approximately 153 litres and 177 litres respectively. The mean residence time of the metabolites ranges from 9 to 14 hours and they are preferentially distributed to the gastro-intestinal tract, kidney, liver and adrenal glands.

Benazepril and benazeprilat are rapidly distributed, mainly in liver and kidney.

Biotransformation

Spironolactone is rapidly and completely metabolised by the liver into its active metabolites, 7- α -thiomethyl-spironolactone and canrenone, which are the primary metabolites in the dog. After co-administration of spironolactone (2 mg/kg bw) and benazepril hydrochloride (0.25 mg/kg bw) the terminal plasma half-lives ($t_{1/2}$) were 7 hours and 6 hours for canrenone and 7- α -thiomethyl-spironolactone respectively.

Benazeprilat concentrations decline biphasically: the initial fast phase represents elimination of free active substance, while the terminal phase reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. After co-administration of spironolactone (2 mg/kg bw) and benazepril hydrochloride (0.25 mg/kg bw) the terminal plasma half-life of benazeprilat ($t_{1/2}$) was 18 hours. Benazepril and benazeprilat are extensively bound to plasma proteins, and in tissues are found mainly in the liver and kidney.

Repeated administration of benazepril leads to slight bioaccumulation of benazeprilat, steady state being achieved within few days.

Elimination

Spironolactone is mainly excreted via its metabolites. The plasma clearances of canrenone and 7- α -thiomethyl-spironolactone are 1.5 l/h/kg bw and 0.9 l/h/kg bw respectively. After the oral administration of radiolabelled spironolactone to the dog, 70% of the dose is recovered in faeces and 20% in the urine.

Benazeprilat is excreted via the biliary and the urinary route in dogs. The clearance of benazeprilat is not affected in dogs with impaired renal function and therefore no adjustment of benazepril dose is required in cases of renal insufficiency

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging: 6 months.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

White plastic (HDPE) bottle with a child-resistant closure in a cardboard box.

Pack sizes of 30 or 90 chewable tablets of **2.5 mg/20 mg, 5 mg/40 mg or 10 mg/80 mg**.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Ceva Santé Animale

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/12/142/001 (1 x 30 chewable tablets, 2.5 mg/20 mg)

EU/2/12/142/002 (1 x 90 chewable tablets, 2.5 mg/20 mg)

EU/2/12/142/003 (1 x 30 chewable tablets, 5 mg/40 mg)

EU/2/12/142/004 (1 x 90 chewable tablets, 5 mg/40 mg)

EU/2/12/142/005 (1 x 30 chewable tablets, 10 mg/80 mg)

EU/2/12/142/006 (1 x 90 chewable tablets, 10 mg/80 mg)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 23/07/2012

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box of 1 bottle of 30 chewable tablets
Cardboard box of 1 bottle of 90 chewable tablets

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cardalis 2.5 mg/20 mg chewable tablets
Cardalis 5 mg/40 mg chewable tablets
Cardalis 10 mg/80 mg chewable tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each chewable tablet contains:

Dog weight 2.5 to 10 kg: benazepril HCl 2.5 mg, spironolactone 20 mg
Dog weight 10 to 20 kg: benazepril HCl 5 mg, spironolactone 40 mg
Dog weight 20 to 80 kg: benazepril HCl 10 mg, spironolactone 80 mg

3. PACKAGE SIZE

30 chewable tablets
90 chewable tablets

4. TARGET SPECIES

Dogs

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Oral use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}
Once opened, use within 6 months.
Once opened, use by...

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER



Ceva Santé Animale

14. MARKETING AUTHORISATION NUMBERS

EU/2/12/142/001 (1 x 30 chewable tablets 2.5 mg/20 mg)

EU/2/12/142/002 (1 x 90 chewable tablets 2.5 mg/20 mg)

EU/2/12/142/003 (1 x 30 chewable tablets 5 mg/40 mg)

EU/2/12/142/004 (1 x 90 chewable tablets 5 mg/40 mg)

EU/2/12/142/005 (1 x 30 chewable tablets 10 mg/80 mg)

EU/2/12/142/006 (1 x 90 chewable tablets 10 mg/80 mg)

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**Bottle of 30 chewable tablets****Bottle of 90 chewable tablets****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cardalis

Cardalis

Cardalis



2.5-10 kg

10-20 kg

20-80 kg

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

benazepril HCl 2.5 mg, spironolactone 20 mg

benazepril HCl 5 mg, spironolactone 40 mg

benazepril HCl 10 mg, spironolactone 80 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp.{mm/yyyy}

Once opened, use by ...

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Cardalis 2.5 mg/20 mg chewable tablets for dogs

Cardalis 5 mg/40 mg chewable tablets for dogs

Cardalis 10 mg/80 mg chewable tablets for dogs

2. Composition

Each chewable tablet contains:

Active substances:

	Benazepril hydrochloride (HCl) (benazeprilum HCl)	Spironolactone (spironolactonum)
Cardalis 2.5 mg/20 mg chewable tablets	2.5 mg	20 mg
Cardalis 5 mg/40 mg chewable tablets	5 mg	40 mg
Cardalis 10 mg/80 mg chewable tablets	10 mg	80 mg

The tablets are brown coloured, palatable, oblong shaped with a score line and chewable.

The chewable tablets can be divided into equal halves.

3. Target species

Dogs.

4. Indications for use

For the treatment of congestive heart failure caused by chronic degenerative valvular disease in dogs (with diuretic support, as appropriate).

5. Contraindications

Do not use during pregnancy and lactation (see section "Pregnancy and lactation").

Do not use in dogs intended or used for breeding.

Do not use in dogs suffering from hypoadrenocorticism, hyperkalaemia or hyponatraemia.

Do not administer in conjunction with Non Steroidal Anti-Inflammatory Drugs (NSAIDs) to dogs with renal insufficiency.

Do not use in cases of hypersensitivity to Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) or to any of the excipients.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

6. Special warnings

Special precautions for safe use in the target species:

Kidney function and serum potassium levels should be evaluated before initiating the treatment with benazepril (hydrochloride) and spironolactone, especially in dogs which may suffer hypoadrenocorticism, hyperkalaemia or hyponatraemia. Unlike in humans, an increased incidence of hyperkalaemia was not observed in clinical trials performed in dogs with this combination. However, regular monitoring of renal function and serum potassium levels is recommended in dogs with renal

impairment, as they may have an increased risk of hyperkalaemia during treatment with this veterinary medicinal product.

Due to the antiandrogenic effect of spironolactone, it is not recommended to administer the veterinary medicinal product to growing dogs.

Reversible prostatic atrophy in entire male dogs treated with spironolactone was noted in a Target Animal Safety study at the recommended dose.

The veterinary medicinal product should be used with caution in dogs with hepatic dysfunction because it may alter the extensive biotransformation of spironolactone in liver.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to spironolactone or benazepril should avoid contact with the veterinary medicinal product.

Pregnant women should take special care to avoid accidental oral exposure because ACE inhibitors have been found to affect the unborn child during pregnancy in humans.

Accidental ingestion, particularly by children, may lead to adverse events such as drowsiness, nausea and vomiting and diarrhoea, and skin rashes.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Pregnancy and lactation:

Do not use during pregnancy and lactation. Embryotoxic effects (foetal urinary tract malformation) were seen in trials of benazepril (as hydrochloride) with laboratory animals (rats) at maternally non-toxic doses.

Interaction with other medicinal products and other forms of interaction:

Furosemide has been used together with this combination of benazepril (hydrochloride) and spironolactone in dogs with heart failure without any clinical evidence of adverse interactions. The concomitant administration of the veterinary medicinal product with other anti-hypertensive agents (e.g. calcium channel blockers, β -blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.

The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments (such as β -blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia (see section "Special precautions for safe use in the target species"). The concomitant use of NSAIDs with this veterinary medicinal product may reduce its anti-hypertensive effect, its natriuretic effect and increase the level of serum potassium. Therefore, dogs treated concomitantly with an NSAID should be closely monitored and correctly hydrated.

The administration of deoxycorticosterone with the veterinary medicinal product may lead to a moderate reduction of the natriuretic effects (reduction of urinary sodium excretion) of spironolactone. Spironolactone decreases digoxin elimination and hence raises digoxin plasma concentration. As the therapeutic index for digoxin is very narrow, it is advisable to monitor closely dogs receiving both digoxin and a combination of benazepril (hydrochloride) and spironolactone.

Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could affect the metabolism of other substances utilizing these metabolic pathways. Therefore, the veterinary medicinal product should be used with caution with other veterinary medicinal products which induce, inhibit, or which are metabolised by these enzymes.

Overdose:

After administration of up to 10 times the recommended dose (2.5 mg/kg bw benazepril hydrochloride, 20 mg/kg spironolactone) to healthy dogs, dose dependent adverse events were noted, see section "Adverse events".

Daily overdoses to healthy dogs, i.e. 6 times (1.5 mg/kg bw benazepril hydrochloride, 12 mg/kg bw spironolactone) and 10 times (2.5 mg/kg bw benazepril hydrochloride, 20 mg/kg bw spironolactone) the recommended dose, led to a slight dose related decrease in red cell mass. However, this very slight decrease was transient, the red cell mass remained within the normal range, and the finding was not considered to be of clinical importance.

A dose related but moderate compensatory physiological hypertrophy of *zona glomerulosa* of the adrenal glands was also observed at doses of 3 times and greater of the recommended dose. This hypertrophy does not seem to be linked to any pathology and was observed to be reversible upon discontinuation of the treatment.

In case of the accidental ingestion by a dog of many chewable tablets of the veterinary medicinal product, there is no specific antidote or treatment. It is therefore recommended to induce vomiting, and then carry out gastric lavage (depending on the risk assessment) and monitor electrolytes.

Symptomatic treatment, e.g., fluid therapy, should also be provided.

7. Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Vomiting, diarrhoea Itching Lethargy, fatigue, anorexia Ataxia, incoordination Elevated creatinine ¹
---	---

¹ May occur at the start of therapy in dogs with chronic kidney disease, due to benazepril action. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents and is therefore not necessarily a reason to stop therapy in the absence of other signs.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system {national system details}.

8. Dosage for each species, routes and method of administration

This fixed combination veterinary medicinal product should only be used in dogs which require both active substances to be administered concomitantly at this fixed dose.

Oral use.

The chewable tablets should be administered to the dog once a day at a dose of 0.25 mg/kg bodyweight benazepril hydrochloride (HCl) and 2 mg/kg bodyweight (bw) spironolactone, according to the following dosage table.

Bodyweight (kg) of dog	Strength and number of chewable tablets to be administered		
	Cardalis 2.5 mg/20 mg chewable tablets	Cardalis 5 mg/40 mg chewable tablets	Cardalis 10 mg/80 mg chewable tablets
2.5 - 5	½		
5 - 10	1		
10 - 20		1	
20 - 40			1
40 - 60			1 + ½
60 - 80			2

9. Advice on correct administration

The chewable tablets should be administered either mixed with a small amount of food offered to the dog just prior to the main meal, or with the meal itself. The chewable tablets contain beef flavouring to improve palatability, and in a field study conducted in dogs with chronic degenerative valvular disease the chewable tablets were voluntarily and fully consumed 92% of the time when offered either with or without food.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after Exp. The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 6 months.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/12/142/001-006

Cardboard box of 30 or 90 chewable tablets for 2.5 mg/20 mg, 5 mg/40 mg or 10 mg/80 mg.

The bottles are fitted with childproof caps.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

10/2025

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse events:

Ceva Santé Animale
8 rue de Logrono 33500 Libourne
France
Tel: +800 35 22 11 51
E-mail: pharmacovigilance@ceva.com

Manufacturer responsible for batch release:

Ceva Santé Animale
Z.I. Tres le Bois
22600 Loudeac
France

Catalent Germany Schorndorf GmbH
Steinbeisstrasse 2
D-73614 Schorndorf
Germany

Ceva Santé Animale
Boulevard de la Communication - Zone Autoroutière
53950 Louverné
France

17. Other information

Pharmacodynamics

Spironolactone and its active metabolites (including 7- α -thiomethyl-spironolactone and canrenone) act as specific antagonists of aldosterone by binding competitively to mineralocorticoid receptors located in the kidneys, heart and blood vessels. In the kidney, spironolactone inhibits the aldosterone-induced sodium retention leading to increase in sodium, and subsequently water excretion, and potassium retention. The resulting reduction in extracellular volume decreases the cardiac preload and left atrial pressure. The result is an improvement in heart function. In the cardiovascular system, spironolactone prevents the detrimental effects of aldosterone. Aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction, although the precise mechanism of action is not yet clearly defined. In experimental models in dogs, it was shown that long term therapy with an

aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure.

Benazepril hydrochloride is a prodrug hydrolysed *in vivo* into its active metabolite, benazeprilat.

Benazeprilat is a highly potent and selective inhibitor of angiotensin converting enzyme (ACE), thus preventing the conversion of inactive angiotensin I to active angiotensin II. Therefore, it blocks effects mediated by angiotensin II, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney.

The veterinary medicinal product causes a long-lasting inhibition of plasma ACE activity in dogs, with more than 95% inhibition at peak effect and significant activity (>80%) persisting 24 hours after dosing.

The association of spironolactone and benazepril is beneficial as both act on the renin-angiotensin-aldosterone system (RAAS) but at different levels along the cascade.

Benazepril, by preventing the formation of Angiotensin-II, inhibits the detrimental effects of vasoconstriction and stimulation of aldosterone release. However, aldosterone release is not fully controlled by ACE Inhibitors because Angiotensin-II is also produced by non-ACE pathways such as chymase (phenomenon known as “aldosterone breakthrough”). Secretion of aldosterone can also be stimulated by factors other than Angiotensin-II, notably K⁺ increase or ACTH. Therefore, to achieve a more complete inhibition of the deleterious effects of RAAS overactivity which occurs with heart failure, it is recommended to use aldosterone antagonists, such as spironolactone, concomitantly with ACE inhibitors to block specifically the activity of aldosterone (regardless of the source), through competitive antagonism on mineralocorticoid receptors. Clinical studies investigating the survival time demonstrated that the fixed combination increased the life expectancy in dogs with congestive heart failure with a 89% reduction in the relative risk of cardiac mortality assessed in dogs treated with spironolactone in combination with benazepril (hydrochloride) compared to dogs treated with benazepril (hydrochloride) alone (mortality was classified as death or euthanasia due to heart failure). It also allowed a quicker improvement of cough and activity and a slower degradation of cough, heart sounds and appetite.

A slight increase in aldosterone blood levels may be observed in animals on treatment. This is thought to be due to activation of feedback mechanisms without adverse clinical consequence. There may be a dose related hypertrophy of the adrenal *zona glomerulosa* at high dose rates. In a field study conducted in dogs with chronic degenerative valvular disease 85.9% of dogs showed good compliance with treatment ($\geq 90\%$ of prescribed chewable tablets successfully administered) over a three-month period.